In August 2011, we recorded a podcast around our ALN-VSP program for the treatment of liver cancers. The discussion was led by our own Jared Gollob, M.D., Senior Director of Clinical Research, and Dr. Geoffrey Shapiro, M.D., Ph.D. of the Dana Farber Cancer Institute.
Listen to podcast discussing ALN-VSP and future of Phase I oncology trials (37.6MB MP3) Read our press release ALN-VSP Ph1 ClinicalStudyResults-ASCO2011 (1.2MB PPT)ALN-VSP RNAi POM-DFCI 2011 (1.8MB PPT)
The focus of the discussion was primarily on the future path of oncology trials, as well as our ALN-VSP program which just recently completed its Phase I clinical trial. The results of this trial were very encouraging, demonstrating safety and tolerability of multiple doses of ALN-VSP in addition to evidence for anti-tumor activity and proof of RNAi mechanism from tissue biopsy samples.
